Clinical Trials Logo

Blepharitis clinical trials

View clinical trials related to Blepharitis.

Filter by:

NCT ID: NCT06400511 Recruiting - Blepharitis Clinical Trials

A Phase 3 Study to Evaluate the Efficacy and Safety of Pimecrolimus 0.3% Ophthalmic Ointment

Start date: April 22, 2024
Phase: Phase 3
Study type: Interventional

The objective of this study is to determine the efficacy and safety of Pimecrolimus 0.3% (MR-139) Ophthalmic Ointment.

NCT ID: NCT06371300 Not yet recruiting - Dry Eye Syndromes Clinical Trials

Photobiomodulation With REd vs BluE Light (REBEL)

Start date: April 2024
Phase: N/A
Study type: Interventional

The use of photobiomodulation or low-level light therapy (LLLT) in the ophthalmic field stemmed from dermatology which has shown impact on skin blood flow and regeneration. There has been a rise in clinical interest with emerging evidence in the benefits of photobiomodulation in managing chronic inflammatory conditions such as dry eye disease including improvements in ocular discomfort symptoms, tear film stability and tear volume. Despite the observed clinical benefits, limited research has been done to compare photobiomodulation utilising different wavelengths, as most research on dry eye disease has focused on red wavelengths. It has been purported that blue wavelengths may disrupt microbial growth while red wavelengths stimulate energy production and hence increase heat in the affected tissues, although research into these differential impacts at the ocular surface and external eye has been limited. Hence, the aim of this exploratory clinical trial is to compare the impact of using LLLT incorporating red versus blue wavelengths on eyelid haemodynamics and microbiome, as well as conventional ocular surface measures of patients with dry eye disease and blepharitis (inflammation of the eyelids). Participants with dry eye disease, oil gland disruption and blepharitis will receive 3 treatments with these LLLT, each separted by 1 week apart, and followed up to 1 month after the final treatment session. Participants will be randomised to either of 3 groups: Red light only group, Red + Blue light group, or a sham treatment group.

NCT ID: NCT06235450 Recruiting - Clinical trials for MicroBlepharoexfoliation, NuLids, iTEAR100, iLIDS100, Blepharitis, Dry Eye Syndrome

A Usability Study of iTEAR100 For Combined EyeLid Microblepharoexfoliation and Neurostimulation

Start date: January 19, 2024
Phase: Phase 1
Study type: Interventional

The purpose of this study is to evaluate the usability of the iTEAR100 generation 2 device in combination with its newly developed iLIDS100 disposable cover.

NCT ID: NCT06182358 Recruiting - Demodex Blepharitis Clinical Trials

Impact of XDEMVY® on Demodex Blepharitis in Soft Contact Lens Wearers

Ariel
Start date: December 27, 2023
Phase: Phase 4
Study type: Interventional

To compare the efficacy of XDEMVY ophthalmic drop to its vehicle control for the treatment of Demodex blepharitis and its impact on the soft contact lens wearing experience.

NCT ID: NCT06054217 Active, not recruiting - Clinical trials for Meibomian Gland Dysfunction

Effect of an Exploratory Vehicle on Meibomian Gland Dysfunction in Patients With Demodex

Rhea
Start date: August 1, 2023
Phase: Phase 2
Study type: Interventional

The purpose of this study is to evaluate and compare the effect of two dosing regimens, BID versus TID dosing, of an Exploratory Vehicle (EV) on meibomian gland dysfunction (MGD) in patients with Demodex lid infestation.

NCT ID: NCT05629390 Completed - Blepharitis Clinical Trials

Trial to Evaluate the Efficacy and Safety of TP-03, LIBRA Study

Start date: October 23, 2022
Phase: Phase 3
Study type: Interventional

The Phase III main study is a randomized, controlled, multicenter, double blind, trial to evaluate the efficacy and safety of TP-03 (lotilaner ophthalmic solution, 0.25%), for the treatment of Demodex blepharitis in Chinese patients. The PK sub-study is a single-arm, open-label trial to evaluate systemic TP-03 in whole blood following topical ocular administration

NCT ID: NCT05608980 Recruiting - Blepharitis Clinical Trials

0.01% Hypochlorous Acid in the Treatment of Blepharitis

Start date: July 1, 2022
Phase: N/A
Study type: Interventional

This is a multi-center, multidisciplinary, open-label, randomized controlled prospective clinical study.

NCT ID: NCT05454956 Completed - Clinical trials for Meibomian Gland Dysfunction

Pilot Study Comparing the Safety and Efficacy of Two Dosing Regimens of TP-03 for the Treatment of MGD

Ersa
Start date: August 3, 2022
Phase: Phase 2
Study type: Interventional

The purpose of this study is to compare the safety and efficacy of TP-03, 0.25%, an eyedrop, BID vs TID dosing regimens for the treatment of meibomian gland dysfunction in patients with Demodex lid infestation.

NCT ID: NCT05160623 Recruiting - Clinical trials for Anterior Blepharitis

Treatment of Blepharitis With Povidone-Iodine 1%

Start date: August 16, 2021
Phase: N/A
Study type: Interventional

One hundred blepharitis patients will be recruited. Each patient will treat one eye once daily with 1% PVI for 30 days by scrubbing the eyelid margin with the solution. The fellow eye will serve as the control and be given the standard treatment (commercial eye wipes). Before treatment initiation, various ocular surface variables will be assessed, such as dry eye grading, subjective discomfort scales, ocular surface questionnaire, and other clinical signs. After 30 days, an identical evaluation will be performed.

NCT ID: NCT05139511 Recruiting - Clinical trials for Meibomian Gland Dysfunction

Analysis of the Results of Intense Pulsed Light Treatment Previously to Laser Refractive Surgery

Start date: February 15, 2021
Phase: N/A
Study type: Interventional

Dry eye is often reported as the most common complication after a laser refractive surgery. Any refractive procedure can lead an impact on the corneal surface and the tear film. The main cause of this dry eye is the corneal denervation caused by the destruction of the anterior stromal nerves during the ablative procedure. This loss of corneal sensitivity leads to a decrease in the blink reflex, a decrease in the secretion rate of the meibomian glands and finally an evaporated dry eye. There is also a chronic inflammation at the corneal surface that produces an increase of inflammatory cytokines and a dysfunction of the meibomian glands. Yu et al have described incidences of dry eye closed to 60% after the first month of LASIK. Hovanesian et al have observed dry eye symptoms in 50% of patients 6 months after surgery. Donnenfeld et al describe 15% of moderate dry eye in the following 3 months and 5% of severe dry eye in the first 6 months. A small number of patients will present with chronic dry eye symptoms for more than 1 year. Bower et al analyzed its incidence in 0.8% Alterations in the tear film also decrease the quality of the retinal image and produce greater number of high-order due to the irregular. Pulsed light therapy (IPL) applied preoperatively in patients who undergo a laser refractive surgery may prevent the post-surgical dry eye and improve the refractive results. The aim of our study is to evaluate the usefulness of the applied therapy for the prevention of dry eye in patients that undergo a corneal refractive procedure.